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Abstract
Background: Pseudomyxoma peritonei (PMP) syndrome is a disease process that typically occurs from ruptured
appendiceal mucocele neoplasms. PMP syndrome arising from malignant transformation of an ovarian primary
mature cystic teratoma (MCT) is a pathogenesis rarely encountered.
Case Presentation: Herein, we report a 28-year-old patient evaluated and treated for a right ovarian mass and large
volume symptomatic abdominopelvic mucinous ascites. Molecular profiling and genetic analysis revealed mutations in ATM, GNAS, and KRAS proteins while IHC demonstrated gastrointestinal-specific staining for CK20, CDX2,
CK7, and SATB2. Peritoneal cytology showed paucicellular mucin. Diffuse peritoneal adenomucinosis (DPAM) variant
of PMP arising from a ruptured ovarian primary MCT after malignant transformation to a low-grade appendiceal-like
mucinous neoplasm was ultimately confirmed. Treatment included staged therapeutic tumor debulking and right
salpingo-oophorectomy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Conclusions: Our report builds upon the existing literature supporting this aggressive treatment option reserved for
advanced abdominal malignancies utilized in this patient with a rare clinical entity.
Keywords: Pseudomyxoma peritonei, Ovarian, Teratoma, Appendiceal mucocele, Disseminated peritoneal
adenomucinosis, Hyperthermic intraperitoneal chemotherapy (HIPEC), Cytoreductive surgery (CRS)
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Introduction
Pseudomyxoma peritonei (PMP) is a rare condition associated with ruptured mucinous neoplasms that typically
originate from the appendix. PMP arising from malignant transformation of an ovarian teratoma is exceedingly rare with a reported incidence of 1-2/1,000,000
per year [1]. PMP syndrome presents with a variable
spectrum of disease biology and malignant potential
but commonly results in widespread mucinous ascites
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disseminated throughout the abdomen and pelvis [2, 3].
If left untreated, patient demise occurs from mass effect
of large accumulations of mucinous ascites and tumorcausing bowel obstruction, perforation, and related
sequela [4]. Computed tomography (CT), magnetic
resonance imaging (MRI), and expert pathologic review
are mandatory to establish PMP diagnosis prior to commencing with treatment [5].
Definitive treatment for PMP is complete gross resection and/or cytoreductive surgical (CRS) removal of all
visible macroscopic tumor burden followed by hyperthermic intraperitoneal chemotherapy (HIPEC) [5, 6].
CRS and HIPEC is a complex surgical procedure that
requires a multidisciplinary team approach [7]. At our
institution, a specialized team of surgeons routinely
provides this treatment in our appendix-derived PMP
patients with optimal oncologic outcomes and low morbidity [8].
In patients with ovaries, determining the origin of PMP
is challenging when a non-appendiceal source is suspected, implicating the possibility of a rare ovarian mucinous tumor etiology. Historically, Ronnett et al. classified
PMP as being ovarian in origin if the appendix cannot be
identified and/or if a rupture of a mucinous tumor of the
appendix goes undetected [2].
Herein, we describe a very rare occurrence of PMP syndrome arising from a ruptured low-grade appendiceallike mucinous neoplasm that evolved from a transformed
ovarian primary mature cystic teratoma (MCT) in a
young patient that was definitively treated by cytoreductive surgery and regional intraperitoneal perfusion with
hyperthermic chemotherapy.

Case report
A 28-year-old female presented to the emergency department for a gynecological consultation after imaging performed at an outside hospital showed a large right ovarian
mass concerning for malignancy. The patient’s presentation followed two months of upper abdominal pain
aggravated by movement, coincident with weight loss,
shortness of breath, abdominal distention and decreased
appetite. Her ultrasound and CT scan showed an 18cm
abdominopelvic mass originating from the right ovary
which was cystic in appearance containing soft tissue,
fatty and calcified components. Importantly, there was
a large volume symptomatic mucinous appearing ascites
(Fig. 1). Serologic tumor markers including CA-125,
CA19-9, and CEA, were normal. Past medical, surgical,
social, and family history were non-contributory.
The patient underwent a two-staged operative
approach. The index procedure included debulking of
symptomatic mucinous ascites and resection of a pelvic mass requiring a right salpingo-oophorectomy. An
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18-cm right ovarian tumor was described within a large
volume of mucinous ascites. Pathology review demonstrated a mature cystic teratoma containing a mucinous
epithelial component (Fig. 2). The ovarian mass contained multiple thick mucoid fluid-filled cysts ranging
in size from 3 to 15cm. In addition, the mass appeared
grossly necrotic with soft tan-gray areas interspersed
among follicles of mature hair. The fallopian tube was
not involved. Neoplastic cells on immunohistochemistry (IHC) were strongly positive for CK20, CDX2, and
SATB2, and focally positive for CK7 (Fig. 2). Pelvic
washings revealed abundant extracellular mucin, paucicellular with scant reactive mesothelial cells. Peritoneal
cytology demonstrated mucicarmine (mucin) staining
of the dense ascites. These clinical and pathologic findings were consistent with the diffuse peritoneal adenomucinosis (DPAM) variant of PMP originating from
a ruptured LAMN-like ectopic mucinous neoplasm
arising from a malignant transformation of an ovarian
mature cystic teratoma. This pathological designation
is in accordance with the recent 2016 Peritoneal Surface Oncology Group International (PSOGI) consensus
for classification and pathologic reporting for PMP and
associated appendiceal neoplasia that recommends distinguishing between the histologic grade of the appendiceal primary and the metastatic peritoneal disease
that occasionally may be discordant [9].
After multidisciplinary review, completion of CRS
and HIPEC was recommended. For the HIPEC portion of the procedure, 40 mg of alkylating agent mitomycin-C (MMC) was employed. The peritoneal cancer
index (PCI) was scored and calculated as described by
Jacquet and Sugarbaker [10]. Calculated total PCI was
21. A complete macroscopic cytoreduction of all diseases was achieved. Procedures included a greater and
lesser omentectomy, omental bursectomy, splenectomy, cholecystectomy, right and left upper quadrant
and subhepatic parietal peritonectomies, partial glissonian capsulectomy, appendectomy, removal of small
bowel mesenteric and serosal implants, total abdominal
hysterectomy, left salpingo-oophorectomy, and pelvic
peritonectomy with cytoreduction of mucinous peritoneal disease implants including resection of the upper
vagina.
Pathology after complete macroscopic cytoreduction
similarly demonstrated abundant pools of paucicellular
mucin on the resected abdominopelvic disease-bearing
visceral and parietal peritoneal surfaces. Importantly, the
appendix was diagnosed as benign on permanent histology. Abundant pools of mucin demonstrated no additional or synchronous malignancy and were confirmatory
for the DPAM-variant of PMP. Outpatient genetic counseling revealed no familial and/or genetic predisposition.
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Fig. 1 A Ultrasound images of the 18-cm mass. B–D Contrast-enhanced perioperative abdominal CT scan of the 18cm mass in the lower
abdominal cavity (B axial, C coronal, D sagittal). The imaging revealed a moderately large volume of mucinous ascites (red arrows) and a large right
ovarian mass (blue arrows) concerning for cystic teratoma vs malignancy

The patient’s tumor was sent for molecular profiling and next-generation sequencing. The genetic report
showed mutations in ATM at splice site 8268+1G>A,
GNAS R201C, and KRAS G12D. The molecular profile
was also consistent with tumor-associated microsatellite
stability with a tumor mutational burden of 3Muts/Mb.
Due to the low-grade nature of the tumor, systemic therapy was not recommended. The patient will undergo a
biannual routine examination and cross-sectional imaging. Currently, there is no evidence of disease recurrence
1 year after the procedure.

Discussion
Mature cystic teratomas (MCTs) otherwise known as
dermoid cysts are benign and frequently present as
ovarian neoplasms. However, in 0.2–2% of cases, they
can undergo malignant transformation, as described in
this patient [11]. The majority of these transformations
develop in post-menopausal patients between the ages
of 50–70 years with squamous cell tumorigenesis, most
commonly reported [11]. Our patient presented at age
28 years [12]. MCTs reportedly can also undergo transformation to adenocarcinomas, basal cell carcinomas,

melanoma, and neuroendocrine tumors due to the
malignant potential of pluripotent cells inherent in these
tumors (Table 1).
PMP syndrome typically arises from perforation and/or
rupture of an appendiceal mucocele or low-grade appendiceal mucocele neoplasms (LAMN) [18, 19]. Extraappendiceal etiologies, although rare, can be ovarian in
origin [2, 3]. Rare incidences have also been reported in
association with neoplastic lesions of other sites including fallopian tube, endocervix, small bowel, colorectum,
stomach, gallbladder, lung, breast, pancreas, mucinous
cysts of spleen, and urachus [20, 21]. High clinical suspicion and evidence supporting an extra-appendiceal origin requires, firstly and importantly, definitive pathologic
confirmation of a normal appendix. Secondly, as published reports describe, IHC staining for SATB2. SATB2
is a protein with restricted expression to glandular cells of
the lower gastrointestinal tract and frequent association
with appendiceal mucinous neoplasms. Lastly, expression
of CK20, CDX2, and CK7 corroborates clinically in our
patient with a PMP-derived ruptured appendiceal mucinous-like tumor arising from a secondary origin, a malignant transformed ovarian mature cystic teratoma [1, 3].
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Fig. 2 A Mucinous neoplasm, right ovary, showing complex mucinous epithelium (200×). B Hair follicles (red arrow) with adjacent mucinous
neoplasm (40×). C SATB2 showing strong nuclear staining (40×). D CDX2/CK20 dual stain showing strong nuclear and cytoplasmic staining,
respectively (40×). E CK7 showing focal cytoplasmic staining

Table 1 Prevalence of malignant transformations of mature
cystic teratomas
Histopathological type

Prevalence (% of MT)

Squamous cell carcinoma

80 [13]

Adenocarcinoma

5 [13]

Transitional cell carcinoma

<1 [14]

Malignant melanoma

0.2–0.8 [15]

Thyroid carcinoma

0.1–0.2 [16]

Carcinoid tumor

<0.1 [17]

The decision to perform cytoreductive surgery is
contingent upon disease biology, disease burden, and
performance status of the patient. In general, limited
abdominopelvic peritoneal metastasis or low peritoneal cancer index (PCI) with a low-grade tumor biology
is a clinical presentation most amenable to this treatment option in healthy patients [22]. Expert pathologic
review is essential prior to proceeding to surgery. Intraoperatively, PCI is determined by scoring the size and/

or confluence of disease and calculating the total score
derived from 13 regions of the abdomen and pelvis (score
range, 0–3; total PCI range, 0–39) [10]. The principles
of surgical cytoreduction of tumor are predicated upon
six peritonectomy and visceral resective procedures that
remove and/or strip cancer from peritoneal abdominopelvic and visceral surfaces as described by Sugarbaker
[23]. Importantly, the pharmacokinetic and clinical efficacy of heated intraperitoneal regional perfusion of
chemotherapy or HIPEC, in part, relies upon successful
removal of macroscopic disease and drug(s) employed
[22]. In our patient’s case, a complete cytoreduction was
performed and mitomycin C, a potent alkylating chemotherapeutic agent with a high molecular weight (334 Daltons) conducive to intraperitoneal drug retention was
utilized to provide an optimal therapeutic concentration
time curve ratio with thermal temperature enhancement
and tumor penetrance [24].
The HIPEC procedure is routinely carried out using
a closed abdomen technique. After cytoreduction of
tumor, inflow, and outflow drainage catheters connected to a perfusion pump are placed within the pelvis
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and upper abdomen, respectively. The patient’s skin is
closed around the catheters with accompanying temperature probes. Regional perfusion of crystalloid containing heated chemotherapy at moderate hyperthermia
temperatures (40–44 °C) is circulated and mechanically
distributed throughout the abdomen and pelvis for a predetermined period of time in accord with the antineoplastic and chemotherapeutic properties of the agent(s)
employed. At the conclusion, drainage catheters and
chemotherapeutic perfusate are removed.
Historically, the first patient treated with hyperthermic
intraperitoneal chemotherapy was in 1979 for recurrent
PMP, having previously undergone CRS. Subsequent
phase I and phase II clinical trials in the 1980s demonstrated the effectiveness of intraperitoneal chemotherapy with improved survival in patients largely suffering
from ovarian and appendiceal cancer. Currently, CRS
and HIPEC are regarded as the standard of care for the
treatment of PMP [5]. Recently, efficacy and survival benefit using HIPEC was reported by van Driel et al. when
implemented as a treatment strategy during interval
cytoreduction for stage III epithelial ovarian cancer in a
multicenter, randomized, phase 3 trial [25]. Moreover,
this treatment approach has shown particular benefit for
abdominal malignancies that include peritoneal mesothelioma, colorectal, and gastric carcinomas [22].
Advanced abdominal malignancies, as in our patient,
frequently present with significant tumor burden and
upper abdominal, hepatobiliary involvement. There is
little debate that suboptimal CRS offers no benefit to
the patient. At our institution, cytoreductive surgery
frequently includes extensive upper abdominal procedures involving consultant hepatobiliary, gastrointestinal (WBB, AN, HL) along with gynecologic surgical
oncologists (SDR, NGR) to optimize the chance for complete macroscopic removal of tumor [8]. As our patient
report entails, PMP arising from a malignant transformed ovarian primary mature cystic teratoma is a rare
“diagnosis of exclusion.” As demonstrated in this current
case, it initially masqueraded as an advanced gynecologic malignancy but on subsequent pathologic review
resembled the DPAM-variant of PMP arising from a
ruptured appendiceal-like neoplasm originating from a
MCT. Importantly from a therapeutic standpoint, complete cytoreduction and HIPEC for the DPAM-variant of
PMP has a 10-year survival rate of 68% [6]. Importantly,
specific experience applying CRS-HIPEC for malignant
transformed ovarian teratomas with peritoneal dissemination, although rarely reported, describes potential
treatment efficacy with modest disease recurrence and
survival [11].
Regardless of origin, PMP has a propensity to
recur despite optimal therapy. Similar to traditional
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appendix-derived PMP, our patient’s tumor harbored
non-targetable mutant KRAS-GNAS co-mutations with
ATM mutant positivity [26]. Presence of these mutations
indeed has a predominant biological impact [27]. To
date, current tumor grade pathologic classification systems for PMP (low grade in our patient) have yet shown
to directly correlate with modern molecular biomarkers.
Advances in molecular characterization of PMP will further enhance our understanding to predict tumor biology
and improve identification of targetable, druggable therapeutic biomarkers to prevent disease recurrence [26].

Conclusion
The present case represents an unusual occurrence and
presentation of a rare clinical entity: a PMP syndrome
arising in appendiceal-like tissue from a mature cystic
teratoma. Discovery of a mature cystic teratoma with
malignant transformations coincident with a PMP syndrome should promptly lead to an investigation into the
malignancy status of the appendix. During surgery for
removal of the mass and/or cytoreduction, the appendix
should be removed and submitted for pathologic analysis.
Notably, CRS and HIPEC are recommended treatments
for appendiceal-derived PMP. However, the question will
remain whether “proof of concept” performance of CRS
and HIPEC will ultimately contribute to similar durable
disease control with PMP-derived from a transformed
MCT. Our case provides a clinical clue and suggests that
it does. This report adds to the existing evidence supporting this aggressive treatment option in these unique
patients. Limitations of this case report include the retrospective nature of this review, duration of follow-up, and
requirement for more patients to validate this treatment
strategy.
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